EMEA-002677-PIP01-19-M02
Key facts
| Active substance |
Delandistrogene moxeparvovec
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0230/2022
|
| PIP number |
EMEA-002677-PIP01-19-M02
|
| Pharmaceutical form(s) |
Solution for infusion
|
| Condition(s) / indication(s) |
Treatment of Duchenne muscular dystrophy
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Roche Registration GmbH
Tel. +41 6168 79411 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|